Last week, drugmaker Endo International released its results for the second quarter of the year. The healthcare company posted revenue of $569.1 million in the period, a decrease of 20 per cent compared to $714 million in the second quarter of 2021. The company also reported a loss of $1.89 billion in its second quarter. Despite the fall in revenue and significant loss, the numbers exceeded the expectations of analysts. After all, the company has been lumbering from crisis to crisis in recent years over its alleged role in fuelling the opioid crisis in the United States. The company has…

Join The Currency

INTRODUCTORY OFFER.

Sign up today: Full annual membership for just €200.

Don’t miss out on what is going on with our daily unique stories from our team of skilled journalists and insightful commentators.

Members of The Currency get full access to over 3,700 exclusive interviews, investigations, and analysis, plus over 360 podcasts.

Annual membership is just €200 for the first year, a saving of €100.

Or try The Currency for the first month for a special introductory rate of €5, a saving of €20.

Cancel at any time.

To become a member today click here.